<p>Mumbai India based Unichem Laboratories announced USFDA approval for its <a href="https://en.wikipedia.org/wiki/Allopurinol">Allopurinol</a> tablets, the tablets will be commercialized from company&amp;rsquo;s Ghaziabad U.P. plant.</p><p>The company has received approval from the <a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration">United States Food and Drug Administration (USFDA</a>) to market generic<a href="https://en.wikipedia.org/wiki/Allopurinol"> Allopurinol</a> tablets in the strengths of 100 mg and 300 mg, Unichem Laboratories said in a filing to BSE.</p><p>The tablets are generic version of Zyloprim tablets, it added.  The tablets are indicated for management of patients with signs and symptoms of primary or secondary gout and those with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels among others.</p><p><strong>About <a href="https://en.wikipedia.org/wiki/Allopurinol">Allopurinol</a>:</strong></p><p><a href="https://en.wikipedia.org/wiki/Allopurinol">Allopurinol,</a> sold under the brand name Zyloprim among others, is a medication used to decrease high blood uric acid levels. It is specifically used to prevent gout, prevent specific types of kidney stones and for the high uric acid levels that can occur with chemotherapy.</p>